Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N plus ), ER-positive breast cancer patients (pts): Results from NSABP B-28

被引：4
|
作者：
Mamounas, E. P.
Tang, G.
Paik, S.
Baehner, F. L.
Liu, Q.
Jeong, J-H
Kim, S-R
Butler, S. M.
Jamshidian, F.
Cherbavaz, D. B.
Sing, A. P.
Shak, S.
Julian, T. B.
Lembersky, B. C.
Wickerham, D. L.
Costantino, J. P.
Wolmark, N.
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, Operat Ctr, Pittsburgh, PA USA
[2] Natl Surg Adjuvant Breast & Bowel Project, Biostat Ctr, Pittsburgh, PA USA
[3] Aultman Hosp, Canton, OH USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA
[5] Genom Hlth Inc, Redwood City, CA USA
[6] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
[7] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-S1-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-10
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Rural versus urban differences among patients (pts) with hormone-receptor positive (HR plus ) breast cancer (BC) and a 21-gene assay recurrence score (RS).
    Andreason, Molly
    Zhang, Chong
    Onitilo, Adedayo A.
    Charlson, John A.
    Ledesma, Wendy M.
    Ridolfi, Kimberly
    Kim, KyungMann
    Wisinski, Kari Braun
    Champeny, Torie L.
    Engel, Jessica Marie
    Millholland, Robert
    Dean, James T.
    Tevaarwerk, Amye
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER+/HER2-breast cancer
    Poorvu, P. D.
    Gelber, S. I.
    Rosenberg, S. M.
    Ruddy, K. J.
    Tamimi, R. M.
    Collins, L. C.
    Peppercorn, J.
    Schapira, L.
    Borges, V. F.
    Come, S. E.
    Warner, E.
    Jakubowski, D. M.
    Russell, C.
    Winer, E. P.
    Partridge, A. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
    Salah Fayaz
    Heba El-Sayed Eissa
    Gerges Attia Demian
    Journal of the Egyptian National Cancer Institute, 32
  • [44] Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
    Fayaz, Salah
    Eissa, Heba El-Sayed
    Demian, Gerges Attia
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2020, 32 (01)
  • [45] Survival Benefit of Adjuvant Chemotherapy in Node-Positive Breast Cancer With a 21-Gene Recurrence Score of 14 to 25: A Real-World Study Based on the Inverse Probability of Treatment Weighting Method
    Ding, Wu
    Ye, Dengfeng
    Zhu, Hongjuan
    Lin, Yingli
    Li, Zhian
    Ruan, Guodong
    CLINICAL BREAST CANCER, 2023, 23 (07) : E441 - E450
  • [46] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
    Dowsett, Mitch
    Cuzick, Jack
    Wale, Christopher
    Forbes, John
    Mallon, Elizabeth A.
    Salter, Janine
    Quinn, Emma
    Dunbier, Anita
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Bugarini, Roberto
    Baehner, Frederick L.
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1829 - 1834
  • [47] A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
    Simons, Martijn J. H. G.
    Machielsen, Peter M.
    Spoorendonk, Jelle A.
    Ignacio, Tim
    Drost, Pieter B.
    Jacobs, Tim
    de Jongh, Felix E.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 445 - 454
  • [48] Breast cancer-specific mortality (BCSM) in patients with node-positive (N plus ) breast cancer (BC) treated based on the 21-gene assay in clinical practice
    Shak, Steven
    McCullough, Debbie
    Petkov, Valentina I.
    CANCER RESEARCH, 2018, 78 (04)
  • [49] Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.
    Penault-Llorca, Frederique Madeleine
    Filleron, Thomas
    Asselain, Bernard
    Baehner, Frederick L.
    Fumoleau, Pierre
    Lacroix-Triki, Magali
    Butler, Steven M.
    Jamshidian, Farid
    Cherbavaz, Diana B.
    Shak, Steven
    Roca, Lise
    Sagan, Christine
    Lemonnier, J.
    Martin, Anne-Laure
    Roche, Henri Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: Experience of Kuwait Cancer Control Center.
    Fayaz, Mohamed Salah
    Eissa, Heba
    Demian, Gerges Attia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345